Systematic review of pre-clinical chronic myeloid leukaemia

Jew Win Kuan, Anselm Ting Su, Leong Chooi Fun, Motomi Osato, Goro Sashida

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Background: Studies of a provisional entity pre-clinical chronic myeloid leukaemia (CML), which precedes chronic phase (CP) without leucocytosis or blood/marrow feature of CML CP, has been increasing. Objective: To perform a systematic review of pre-clinical CML and analysis the data relevant to disease progression to CML CP. Method: We performed a literature search on 16 July 2017 using EBSCOhost Research Databases interface and Western Pacific Region Index Medicus. Two authors selected the studies, extracted the data and evaluated the quality of studies using an 8-item tool, independently. The outcomes were percentage of Philadelphia chromosome in the number of metaphases examined (Ph%), correlation between Ph% and blood count and time progress to CML. Result: Our initial search returned 4770 studies. A total of 10 studies with a total 17 subjects were included. The lowest Ph%, which eventually progresses to CML, was 10%. Absolute basophil count seemed to correlate better with Ph% compared to total white cell and absolute eosinophil count. The time from the first documented pre-clinical CML to CML ranged from 12 to 48 months. The overall quality of the included studies was average. Conclusion: This is the first systematic review on pre-clinical CML. This entity requires additional large-scale studies.

Original languageEnglish
Pages (from-to)465-484
Number of pages20
JournalInternational Journal of Hematology
Volume108
Issue number5
DOIs
Publication statusPublished - 1 Nov 2018

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Chronic Phase
Philadelphia Chromosome
Basophils
Leukocytosis
Metaphase
Eosinophils
MEDLINE
Disease Progression
Bone Marrow
Databases
Research

Keywords

  • Asymptomatic
  • Chronic myeloid leukaemia
  • Pre-clinical
  • Smoldering

ASJC Scopus subject areas

  • Hematology

Cite this

Systematic review of pre-clinical chronic myeloid leukaemia. / Kuan, Jew Win; Su, Anselm Ting; Chooi Fun, Leong; Osato, Motomi; Sashida, Goro.

In: International Journal of Hematology, Vol. 108, No. 5, 01.11.2018, p. 465-484.

Research output: Contribution to journalReview article

Kuan, Jew Win ; Su, Anselm Ting ; Chooi Fun, Leong ; Osato, Motomi ; Sashida, Goro. / Systematic review of pre-clinical chronic myeloid leukaemia. In: International Journal of Hematology. 2018 ; Vol. 108, No. 5. pp. 465-484.
@article{e69dcd38236b44fe8d38bdf1fe4da376,
title = "Systematic review of pre-clinical chronic myeloid leukaemia",
abstract = "Background: Studies of a provisional entity pre-clinical chronic myeloid leukaemia (CML), which precedes chronic phase (CP) without leucocytosis or blood/marrow feature of CML CP, has been increasing. Objective: To perform a systematic review of pre-clinical CML and analysis the data relevant to disease progression to CML CP. Method: We performed a literature search on 16 July 2017 using EBSCOhost Research Databases interface and Western Pacific Region Index Medicus. Two authors selected the studies, extracted the data and evaluated the quality of studies using an 8-item tool, independently. The outcomes were percentage of Philadelphia chromosome in the number of metaphases examined (Ph{\%}), correlation between Ph{\%} and blood count and time progress to CML. Result: Our initial search returned 4770 studies. A total of 10 studies with a total 17 subjects were included. The lowest Ph{\%}, which eventually progresses to CML, was 10{\%}. Absolute basophil count seemed to correlate better with Ph{\%} compared to total white cell and absolute eosinophil count. The time from the first documented pre-clinical CML to CML ranged from 12 to 48 months. The overall quality of the included studies was average. Conclusion: This is the first systematic review on pre-clinical CML. This entity requires additional large-scale studies.",
keywords = "Asymptomatic, Chronic myeloid leukaemia, Pre-clinical, Smoldering",
author = "Kuan, {Jew Win} and Su, {Anselm Ting} and {Chooi Fun}, Leong and Motomi Osato and Goro Sashida",
year = "2018",
month = "11",
day = "1",
doi = "10.1007/s12185-018-2528-x",
language = "English",
volume = "108",
pages = "465--484",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Systematic review of pre-clinical chronic myeloid leukaemia

AU - Kuan, Jew Win

AU - Su, Anselm Ting

AU - Chooi Fun, Leong

AU - Osato, Motomi

AU - Sashida, Goro

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Background: Studies of a provisional entity pre-clinical chronic myeloid leukaemia (CML), which precedes chronic phase (CP) without leucocytosis or blood/marrow feature of CML CP, has been increasing. Objective: To perform a systematic review of pre-clinical CML and analysis the data relevant to disease progression to CML CP. Method: We performed a literature search on 16 July 2017 using EBSCOhost Research Databases interface and Western Pacific Region Index Medicus. Two authors selected the studies, extracted the data and evaluated the quality of studies using an 8-item tool, independently. The outcomes were percentage of Philadelphia chromosome in the number of metaphases examined (Ph%), correlation between Ph% and blood count and time progress to CML. Result: Our initial search returned 4770 studies. A total of 10 studies with a total 17 subjects were included. The lowest Ph%, which eventually progresses to CML, was 10%. Absolute basophil count seemed to correlate better with Ph% compared to total white cell and absolute eosinophil count. The time from the first documented pre-clinical CML to CML ranged from 12 to 48 months. The overall quality of the included studies was average. Conclusion: This is the first systematic review on pre-clinical CML. This entity requires additional large-scale studies.

AB - Background: Studies of a provisional entity pre-clinical chronic myeloid leukaemia (CML), which precedes chronic phase (CP) without leucocytosis or blood/marrow feature of CML CP, has been increasing. Objective: To perform a systematic review of pre-clinical CML and analysis the data relevant to disease progression to CML CP. Method: We performed a literature search on 16 July 2017 using EBSCOhost Research Databases interface and Western Pacific Region Index Medicus. Two authors selected the studies, extracted the data and evaluated the quality of studies using an 8-item tool, independently. The outcomes were percentage of Philadelphia chromosome in the number of metaphases examined (Ph%), correlation between Ph% and blood count and time progress to CML. Result: Our initial search returned 4770 studies. A total of 10 studies with a total 17 subjects were included. The lowest Ph%, which eventually progresses to CML, was 10%. Absolute basophil count seemed to correlate better with Ph% compared to total white cell and absolute eosinophil count. The time from the first documented pre-clinical CML to CML ranged from 12 to 48 months. The overall quality of the included studies was average. Conclusion: This is the first systematic review on pre-clinical CML. This entity requires additional large-scale studies.

KW - Asymptomatic

KW - Chronic myeloid leukaemia

KW - Pre-clinical

KW - Smoldering

UR - http://www.scopus.com/inward/record.url?scp=85053438517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053438517&partnerID=8YFLogxK

U2 - 10.1007/s12185-018-2528-x

DO - 10.1007/s12185-018-2528-x

M3 - Review article

C2 - 30218276

AN - SCOPUS:85053438517

VL - 108

SP - 465

EP - 484

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 5

ER -